Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this second episode, we discuss the management of skin reactions associated with enfortumab vedotin, or EV.
Our Guests:
In this episode, Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC interviews dermatology specialist, Dr. Joel Claveau.
Dr. Joel Claveau is a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.